Primary aldosteronism: an unsuspected culprit of hypertension in systemic lupus erythematosus?

Grace S. Feng (Leading Author), Joanna R. Kent (Leading Author), Peter J. Fuller, Alberta Y. Hoi, A. Richard Kitching, Jun Yang (Leading Author), Fabien B. Vincent (Leading Author)

Research output: Contribution to journalReview ArticleResearchpeer-review


Primary aldosteronism (PA) is the most common endocrine cause of secondary hypertension and is associated with a high risk of cardiovascular disease in the general population. Patients suffering from systemic lupus erythematosus (SLE), a multisystem and multifactorial autoimmune disease, experience a high burden of hypertension and cardiovascular disease. Importantly, cardiovascular disease is one of the leading causes of death in SLE. Very limited evidence suggests an increased proportion of autoimmune diseases such as SLE in patients with PA. However, studies evaluating the prevalence of PA in the SLE population are lacking. Despite the potential for curative or targeted treatments, guidelines for the management of hypertension in SLE do not currently recommend testing for PA. This review highlights PA as a potentially over-looked secondary cause of hypertension in SLE, and offers future directions in research to improve the detection of this highly modifiable cardiovascular risk factor in the SLE population.

Original languageEnglish
Pages (from-to)2312-2322
Number of pages11
JournalClinical and Experimental Rheumatology
Issue number11
Publication statusPublished - 1 Nov 2023

Cite this